Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 681
Filtrar
1.
Phytomedicine ; 128: 155589, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38608487

RESUMEN

BACKGROUND: Food products undergo a pronounced Maillard reaction (MR) during the cooking process, leading to the generation of substantial quantities of Maillard reaction products (MRPs). Within this category, advanced glycation end products (AGEs), acrylamide (AA), and heterocyclic amines (HAs) have been implicated as potential risk factors associated with the development of diseases. PURPOSE: To explore the effects of polyphenols, a class of bioactive compounds found in plants, on the inhibition of MRPs and related diseases. Previous research has mainly focused on their interactions with proteins and their effects on the gastrointestinal tract and other diseases, while fewer studies have examined their inhibitory effects on MRPs. The aim is to offer a scientific reference for future research investigating the inhibitory role of polyphenols in the MR. METHODS: The databases PubMed, Embase, Web of Science and The Cochrane Library were searched for appropriate research. RESULTS: Polyphenols have the potential to inhibit the formation of harmful MRPs and prevent related diseases. The inhibition of MRPs by polyphenols primarily occurs through the following mechanisms: trapping α-dicarbonyl compounds, scavenging free radicals, chelating metal ions, and preserving protein structure. Simultaneously, polyphenols exhibit the ability to impede the onset and progression of related diseases such as diabetes, atherosclerosis, cancer, and Alzheimer's disease through diverse pathways. CONCLUSION: This review presents that inhibition of polyphenols on Maillard reaction products and their induction of related diseases. Further research is imperative to enhance our comprehension of additional pathways affected by polyphenols and to fully uncover their potential application value in inhibiting MRPs.


Asunto(s)
Productos Finales de Glicación Avanzada , Reacción de Maillard , Polifenoles , Polifenoles/farmacología , Polifenoles/química , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Humanos , Acrilamida/química , Enfermedad de Alzheimer/tratamiento farmacológico , Neoplasias/tratamiento farmacológico , Aterosclerosis/tratamiento farmacológico , Aterosclerosis/prevención & control , Animales
2.
Eur J Pharmacol ; 927: 175072, 2022 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-35636523

RESUMEN

As the irreversible products of the non-enzymatic reduction of sugars and the amino groups of proteins or peptides, advanced glycation end products (AGEs) are metabolized and excreted via the kidneys. However, if AGEs are not metabolized, they are deposited in the kidneys and bind to AGE receptors (RAGE), which can induce various pathological changes, including oxidative stress, apoptosis, and inflammation. This study used the D-galactose (DG)-induced rat model to explore the potential role and mechanism of L-theanine in inhibiting AGEs/RAGE-related signaling pathways in renal tissues. L-theanine increased the activities of glutathione peroxidase (GSH-Px) and total antioxidant capacity (T-AOC) while downregulating the contents of malondialdehyde (MDA) and AGEs in renal tissues induced by DG (P < 0.05). By inhibiting the upregulation of RAGE protein expression attributed to AGEs accumulation (P < 0.05), L-theanine downregulated phosphorylated nuclear factor (p-NF-κB (p65)), Bax, and cleaved-caspase-3 expression and increased Bcl-2 protein expression (P < 0.05), thereby alleviating the oxidative stress damage and reducing the inflammation and cell injury induced by DG. In addition, the Congo red staining section of renal tissue also showed that the natural product L-theanine can protect against AGEs-induced renal damage in DG-induced rat model.


Asunto(s)
Galactosa , Glutamatos , Productos Finales de Glicación Avanzada , Receptor para Productos Finales de Glicación Avanzada , Animales , Galactosa/farmacología , Glutamatos/farmacología , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Productos Finales de Glicación Avanzada/metabolismo , Inflamación/metabolismo , Riñón/metabolismo , Estrés Oxidativo , Ratas , Receptor para Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Receptor para Productos Finales de Glicación Avanzada/metabolismo , Transducción de Señal/efectos de los fármacos
3.
Int J Mol Sci ; 23(3)2022 Jan 20.
Artículo en Inglés | MEDLINE | ID: mdl-35163025

RESUMEN

The glycation process has been recognized as one of the critical parameters that accelerate signs of skin aging, especially in skin exposed to environment factors, such as ultraviolet radiation. Although previous studies showed the anti-inflammatory and antiaging properties of the hydrolyzed collagen tripeptide (CTP), its exact mechanism is not fully understood. Therefore, in this study, we sought to investigate the effect of a topical CTP on facial skin. Our group designed a 4 week prospective, single-arm study of 22 Asian women who applied topical CTP. We observed significant improvements in skin wrinkles, elasticity, and density with a reduction in skin accumulation of advanced glycated end products (AGEs) at week 4 without any adverse effects. The in vitro study revealed a preventive effect of the topical CTP on the accumulation of AGEs, denatured collagen production, and reactive oxygen species in dermal fibroblasts. Moreover, treatment with the CTP decreased induction of matrix metalloproteinases while increasing the collagen 1 level. These results suggest that the application of a topical CTP might improve clinical aging phenotypes via the inhibition of glycation and oxidative stress, leading to a delay in cellular aging.


Asunto(s)
Senescencia Celular/efectos de los fármacos , Colágeno/farmacología , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Estrés Oxidativo , Fragmentos de Péptidos/farmacología , Envejecimiento de la Piel/efectos de los fármacos , Piel/efectos de los fármacos , Adulto , Estudios de Casos y Controles , Elasticidad , Femenino , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Glicosilación , Humanos , Persona de Mediana Edad , Proyectos Piloto , Estudios Prospectivos , Especies Reactivas de Oxígeno/metabolismo , Piel/metabolismo , Envejecimiento de la Piel/patología
4.
Nutrients ; 13(11)2021 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-34836321

RESUMEN

Hyperglycemia, when sustained over a long time in diabetes mellitus (DM), leads to biochemical and cellular abnormalities, primarily through the formation of advanced glycation end-products (AGEs). In the treatment of diabetes, beside blood-sugar-lowering medications, a consumption of herbal products that can inhibit the AGEs' formation is recommended. This study investigated the in vitro antiglycoxidative potential of extracts and fractions from the rhizomes of Japanese, Giant, and Bohemian knotweeds (Reynoutria japonica (Houtt.), R. sachalinensis (F. Schmidt) Nakai, and R.× bohemica Chrtek et Chrtkova). Their effects on glycooxidation of bovine and human serum albumin were evaluated by incubation of the proteins with a mixture of glucose and fructose (0.5 M) and 150 µg/mL of extract for 28 days at 37 °C, followed by measuring early and late glycation products, albumin oxidation (carbonyl and free thiol groups), and amyloid-ß aggregation (thioflavin T and Congo red assays). The highest antiglycoxidative activity, comparable or stronger than the reference drug (aminoguanidine), was observed for ethyl acetate and diethyl ether fractions, enriched in polyphenols (stilbenes, phenylpropanoid disaccharide esters, and free and oligomeric flavan-3-ols). In conclusion, the antiglycoxidative compounds from these three species should be further studied for potential use in the prevention and complementary treatment of DM.


Asunto(s)
Antioxidantes/farmacología , Hipoglucemiantes/farmacología , Extractos Vegetales/farmacología , Reynoutria , Rizoma , Acetatos/farmacología , Animales , Bovinos , Diabetes Mellitus/sangre , Diabetes Mellitus/tratamiento farmacológico , Éter/farmacología , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Glicosilación/efectos de los fármacos , Humanos , Oxidación-Reducción/efectos de los fármacos , Polifenoles/farmacología , Albúmina Sérica/metabolismo , Albúmina Sérica Bovina/metabolismo
5.
Bioorg Med Chem Lett ; 54: 128444, 2021 12 15.
Artículo en Inglés | MEDLINE | ID: mdl-34763082

RESUMEN

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Many studies have shown a significant increase in the marker signal of the receptor for advanced glycation end-products (RAGE) with the malignant progression of tumor growth, metastasis and recurrence of breast cancer, including TNBC of primary tumors and lymph node metastases. Azeliragon is a RAGE inhibitor and it has been shown to actively inhibit the TNBC cell line, SUM149 (IC50 = 5.292 ± 0.310 µM). In order to develop a new anti-TNBC agent, we designed, synthesized and screened 26 Azeliragon triazole analogues to determine their anti-TNBC activities in vitro. The most active compound was KC-10 with an IC50 value of 0.220 ± 0.034 µM.


Asunto(s)
Antineoplásicos/farmacología , Diseño de Fármacos , Imidazoles/farmacología , Triazoles/farmacología , Neoplasias de la Mama Triple Negativas/tratamiento farmacológico , Antineoplásicos/síntesis química , Antineoplásicos/química , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Productos Finales de Glicación Avanzada/metabolismo , Humanos , Imidazoles/síntesis química , Imidazoles/química , Estructura Molecular , Relación Estructura-Actividad , Triazoles/síntesis química , Triazoles/química , Neoplasias de la Mama Triple Negativas/patología
6.
Biomed Pharmacother ; 144: 112336, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34678719

RESUMEN

Natural products exist in various natural foods such as plants, herbs, fruits, and vegetables. Furthermore, marine life offers potential natural products with significant biological activity. The biochemical reaction is known as advanced glycation end products (AGEs) occurs in the human body. On the other hand, foods are capable of a wide range of processing conditions resulting in the generation of exogenous AGEs adducts. Protein glycation and the formation of advanced glycation end products both contribute to the pathogenesis of hyperglycemic complications. AGEs also play a pivotal role in microvascular and macrovascular complications progression by receptors for advanced glycation end products (RAGE). RAGE activate by AGEs leads to up-regulation of transcriptional factor NF-kB and inflammatory genes. Around the globe, researchers are working in various approaches for therapeutical implications on controlling AGEs mediated disease complications. In this regard, one of the potential promising agents observed with a wide range of AGEs inhibition by food-derived natural products. Current biotechnological tools have been turned to natural products or phytochemicals to manufacture the molecules without compromising their functionality. Metabolic engineering and bioinformatics perspectives have recently enabled the generation of a few potent metabolites with anti-diabetic activity. As the primary focus, this review article will also discuss multidisciplinary approaches that emphasize current advances in anti-diabetic therapeutic action and future perspectives of natural products.


Asunto(s)
Productos Biológicos/uso terapéutico , Glucemia/efectos de los fármacos , Diabetes Mellitus/tratamiento farmacológico , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Hipoglucemiantes/uso terapéutico , Fitoquímicos/uso terapéutico , Fitoterapia , Preparaciones de Plantas/uso terapéutico , Animales , Productos Biológicos/aislamiento & purificación , Biomarcadores/sangre , Glucemia/metabolismo , Diabetes Mellitus/sangre , Productos Finales de Glicación Avanzada/metabolismo , Humanos , Hipoglucemiantes/aislamiento & purificación , Resistencia a la Insulina , Fitoquímicos/aislamiento & purificación , Preparaciones de Plantas/aislamiento & purificación
7.
Molecules ; 26(17)2021 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-34500753

RESUMEN

Oxidative stress is one of the significant precursors of various metabolic diseases such as diabetes, Parkinson's disease, cardiovascular diseases, cancer, etc. Various scientific reports have indicated that secondary plant metabolites play an important role in preventing oxidative stress and its harmful effects. In this respect, this study was planned to investigate the phenolic profile and antioxidant and antidiabetic potentials of the aqueous extracts from Turkish Cistus species by employing in vitro methods. In vitro digestion simulation procedure was applied to all extracts to estimate the bioavailability of their phenolic contents. Total phenolic, flavonoid, phenolic acid and proanthocyanidin contents were determined for all phases of digestion. In addition, changes in the quantity of the assigned marker flavonoids (tiliroside, hyperoside and quercitrin) were monitored by High-Performance Thin Layer Chromatography (HPTLC) analysis. The antioxidant activity potentials of the extracts were studied by various methods to reveal their detailed activity profiles. On the other hand, in vitro α-amylase and α-glucosidase enzymes and advanced-glycation end product (AGE) inhibitory activities of the extracts were determined to evaluate the antidiabetic potentials of extracts. The results showed that aqueous extracts obtained from the aerial parts of Turkish Cistus species have rich phenolic contents and potential antioxidant and antidiabetic activities; however, their bioactivity profiles and marker flavonoid concentrations might significantly be affected by human digestion. The results exhibited that total phenolic contents, antioxidant activities and diabetes-related enzyme inhibitions of the bioavailable samples were lower than non-digested samples in all extracts.


Asunto(s)
Antioxidantes/farmacología , Cistus/química , Diabetes Mellitus/tratamiento farmacológico , Hipoglucemiantes/farmacología , Fenoles/farmacología , Extractos Vegetales/farmacología , Antioxidantes/química , Antioxidantes/metabolismo , Compuestos de Bifenilo/antagonistas & inhibidores , Cistus/metabolismo , Diabetes Mellitus/metabolismo , Relación Dosis-Respuesta a Droga , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Productos Finales de Glicación Avanzada/metabolismo , Humanos , Hipoglucemiantes/química , Hipoglucemiantes/metabolismo , Estructura Molecular , Estrés Oxidativo/efectos de los fármacos , Fenoles/química , Fenoles/metabolismo , Picratos/antagonistas & inhibidores , Extractos Vegetales/química , Extractos Vegetales/metabolismo , Relación Estructura-Actividad , Turquía , Agua/química , alfa-Amilasas/antagonistas & inhibidores , alfa-Amilasas/metabolismo , alfa-Glucosidasas/metabolismo
8.
Bioorg Chem ; 114: 105098, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34153812

RESUMEN

Investigation of chemical constituents of Masclura tricuspidata leaves resulted in the isolation of 47 isoflavonoids possessing prenyl groups with different numbers and structures. Among them, sixteen compounds named cudracusisoflavones A-P (1-16) were first isolated from nature. The isoflavonoids isolated from M. tricuspidata leaves showed anti-diabetic effects as measured by inhibition on α-glucosidase activity and advanced glycation end-products (AGEs) formations. Especially, cudracusisoflavone L (12), a new compound, together with gancaonin M (27), erysenegalensein E (41) and millewanin G (44) showed strong α-glucosidase inhibition with IC50 values <10.0 µM. In addition, cudracusisoflavones A (1), D (4), M (13) and N (14), together with known prenylated isoflavonoids efficiently inhibited methylglyoxal (MGO)- or glyoxal (GO)-induced AGE formations. Structure activity relationship together with molecular docking analysis suggested the importance of hydroxy group and linear type of prenyl moiety for α-glucosidase inhibition. Conclusively, diverse prenylated isoflavonoids in M. tricuspidata leaves might ameliorate glycotoxicity-induced metabolic diseases.


Asunto(s)
Flavonoides/farmacología , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Inhibidores de Glicósido Hidrolasas/farmacología , Hipoglucemiantes/farmacología , Moraceae/química , alfa-Glucosidasas/metabolismo , Relación Dosis-Respuesta a Droga , Flavonoides/química , Flavonoides/aislamiento & purificación , Productos Finales de Glicación Avanzada/metabolismo , Inhibidores de Glicósido Hidrolasas/química , Inhibidores de Glicósido Hidrolasas/aislamiento & purificación , Glicosilación/efectos de los fármacos , Hipoglucemiantes/química , Hipoglucemiantes/aislamiento & purificación , Simulación del Acoplamiento Molecular , Estructura Molecular , Hojas de la Planta/química , Saccharomyces cerevisiae/enzimología , Relación Estructura-Actividad
9.
Food Chem ; 362: 130169, 2021 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-34102509

RESUMEN

Advanced glycation end-products (AGEs) are produced during protein glycation and associated with diabetic complications. Peanut skin is rich in procyanidins, which may be used as an inhibitor of glycation. This study evaluated the potential anti-glycation effect of peanut skin extract (PSE) and dissected the underlying mechanism. PSE could effectively inhibit the formation of AGEs in BSA-Glc and BSA-MGO/GO models, with 44%, 37% and 82% lower IC50 values than the positive control (AG), respectively. The inhibitory effect of PSE on BSA glycation might be ascribed to its binding interaction with BSA, attenuated formation of early glycation products and trapping of reactive dicarbonyl compounds. Notably, PSE showed a remarkably stronger inhibitory effect on Amadori products than AG. Furthermore, three new types of PSE-MGO adducts were formed as identified by UPLC-Q-TOF-MS. These findings suggest that PSE may serve as an inhibitor of glycation and provide new insights into its application.


Asunto(s)
Arachis/química , Productos Finales de Glicación Avanzada/química , Extractos Vegetales/química , Fructosamina/química , Glucosa/química , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Extractos Vegetales/análisis , Proantocianidinas/análisis , Proantocianidinas/química , Piruvaldehído/química , Albúmina Sérica Bovina/química
10.
Biomed Pharmacother ; 140: 111750, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34051615

RESUMEN

Advanced glycation end products (AGEs) are a group of complex compounds generated by nonenzymatic interactions between proteins and reducing sugars or lipids. AGEs accumulate in vivo and activate various signaling pathways closely related to the occurrence of various chronic metabolic diseases. In this paper, we describe the process through which AGEs are formed, the classification of AGEs, and biological effects of AGEs on human health. Most importantly, we review recent progress in natural compound-based AGE formation inhibitors. Major classes of natural inhibitors, including polyphenols, polysaccharides, terpenoids, vitamins and alkaloids, have been described. Their mechanisms of action have been summarized as scavenging free radicals, chelating metal ions, capturing active carbonyl compounds, protecting protein glycation sites, and lowering blood glucose levels. Although these natural compounds have good antiglycation activity, to date, they are not widely used in the clinic, likely because of their low content levels. However, these natural compounds and their molecular frameworks will play a valuable role in inspiring drug discovery.


Asunto(s)
Productos Biológicos/farmacología , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Animales , Productos Finales de Glicación Avanzada/metabolismo , Humanos
11.
Arch Pharm Res ; 44(4): 378-401, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33837513

RESUMEN

The role of advanced glycation end products (AGEs) is not limited to diabetes and diabetes-related complications. There are multiple modulators, including the receptor for advanced glycation end products, high mobility group box 1, glyoxalase 1, nuclear factor-kappa B, tumor necrosis factor-α, chronic unpredictable stress, reactive oxygen species, and inflammatory cytokines, which interact with AGE signaling and control diabetes, modulating these interacting modulators. The progression of diabetes, as well as related complications, can be controlled and treated. Natural products rich in bioactive constituents can interact with AGEs and their related mediators through various signaling cascades, thereby controlling and preventing the progression of diabetes. This review provides a deeper assessment of the signaling pathway, interactions between phytochemicals and AGEs, and its mediators, to develop a multifold therapeutic approach to prevent and treat diabetes and its related complications.


Asunto(s)
Diabetes Mellitus/tratamiento farmacológico , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Hipoglucemiantes/antagonistas & inhibidores , Fitoquímicos/farmacología , Animales , Productos Finales de Glicación Avanzada/metabolismo , Humanos , Hipoglucemiantes/efectos adversos , Hipoglucemiantes/farmacología , Fitoquímicos/química , Transducción de Señal/efectos de los fármacos
12.
Bioorg Chem ; 111: 104844, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33798848

RESUMEN

Ginseng (Panax ginseng and red ginseng) extract has been reported to inhibit the formation of advanced glycation end-products (AGEs); however, the potential inhibitory activity of its major constituents (ginsenosides) against AGE formation is still unknown. In the present study, we investigated the inhibitory effect of ginsenoside derivatives on AGE formation. Herein, we assessed the activity of 22 ginsenosides, most of which significantly inhibited fluorescent AGE formation. Notably, ginsenoside Rh2, ginsenoside Rh1, and compound K exhibited the most potent AGE inhibitory potential with IC50 values of 3.38, 8.42, and 10.85 µM, respectively. The structure- activity relationship revealed that the presence of sugar moieties, hydroxyl groups, and their linkages, and the stereostructure of the ginsenoside skeleton played an important role in the inhibition of AGE formation. Furthermore, the inhibitory activity of the most active ginsenoside Rh2 on fructose-glucose-mediated protein glycation and oxidation of bovine serum albumin (BSA) was explored. Rh2 (0.1-12.5 µM) inhibited the formation of fluorescent AGE and non-fluorescent AGE, as well as the level of fructosamine and prevented protein oxidation by decreasing protein carbonyl formation and protein thiol group modification. Rh2 also suppressed the formation of the ß-cross amyloid structure of BSA. Ginsenosides might be promising new anti-glycation agents for the prevention of diabetic complications via inhibition of AGE formation and oxidation-dependent protein damage.


Asunto(s)
Descubrimiento de Drogas , Ginsenósidos/farmacología , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Panax/química , Albúmina Sérica Bovina/antagonistas & inhibidores , Animales , Bovinos , Relación Dosis-Respuesta a Droga , Fructosa/metabolismo , Ginsenósidos/química , Ginsenósidos/aislamiento & purificación , Glucosa/metabolismo , Productos Finales de Glicación Avanzada/metabolismo , Glicosilación/efectos de los fármacos , Estructura Molecular , Albúmina Sérica Bovina/metabolismo , Relación Estructura-Actividad
13.
Biosci Biotechnol Biochem ; 85(5): 1069-1076, 2021 Apr 24.
Artículo en Inglés | MEDLINE | ID: mdl-33704410

RESUMEN

(-)-Epigallocatechin gallate (EGCG) and olivetol hybrid molecules 1-4 were conveniently synthesized using dielectric barrier discharge plasma irradiation. The structures of these unprecedented hybrid molecules were determined by interpretation of spectroscopic data. The unusual hybrid 1 showed improved antiglycation potency toward the advanced formation of glycation end products than the original EGCG and olivetol. The novel hybrid 1 is an interesting new class of antiglycation candidate that requires further investigation.


Asunto(s)
Catequina/análogos & derivados , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Resorcinoles/química , Albúmina Sérica Bovina/química , Animales , Catequina/química , Catequina/farmacología , Bovinos , Técnicas de Química Sintética , Fructosa/química , Glucosa/química , Productos Finales de Glicación Avanzada/química , Glicosilación/efectos de los fármacos , Espectroscopía de Resonancia Magnética , Gases em Plasma/química , Resorcinoles/farmacología , Soluciones
14.
Nutrients ; 13(2)2021 Feb 08.
Artículo en Inglés | MEDLINE | ID: mdl-33567596

RESUMEN

Caffeic acid is one of the most abundant hydroxycinnamic acids in fruits, vegetables, and beverages. This phenolic compound reaches relevant concentrations in the colon (up to 126 µM) where it could come into contact with the intestinal cells and exert its anti-inflammatory effects. The aim of this investigation was to study the capacity of caffeic acid, at plausible concentrations from an in vivo point of view, to modulate mechanisms related to intestinal inflammation. Consequently, we tested the effects of caffeic acid (50-10 µM) on cyclooxygenase (COX)-2 expression and prostaglandin (PG)E2, cytokines, and chemokines (IL-8, monocyte chemoattractant protein-1 -MCP-1-, and IL-6) biosynthesis in IL-1ß-treated human myofibroblasts of the colon, CCD-18Co. Furthermore, the capacity of caffeic acid to inhibit the angiotensin-converting enzyme (ACE) activity, to hinder advanced glycation end product (AGE) formation, as well as its antioxidant, reducing, and chelating activity were also investigated. Our results showed that (i) caffeic acid targets COX-2 and its product PGE2 as well as the biosynthesis of IL-8 in the IL-1ß-treated cells and (ii) inhibits AGE formation, which could be related to (iii) the high chelating activity exerted. Low anti-ACE, antioxidant, and reducing capacity of caffeic acid was also observed. These effects of caffeic acid expands our knowledge on anti-inflammatory mechanisms against intestinal inflammation.


Asunto(s)
Antiinflamatorios/farmacología , Ácidos Cafeicos/farmacología , Gastroenteritis/tratamiento farmacológico , Intestinos/efectos de los fármacos , Miofibroblastos/efectos de los fármacos , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Antioxidantes/farmacología , Quelantes/farmacología , Quimiocinas/efectos de los fármacos , Colon/citología , Colon/efectos de los fármacos , Ciclooxigenasa 2/efectos de los fármacos , Citocinas/efectos de los fármacos , Dinoprostona/antagonistas & inhibidores , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Humanos , Inflamación , Interleucina-1beta/biosíntesis , Intestinos/citología
15.
J Food Sci ; 86(2): 579-586, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33448051

RESUMEN

Advanced glycation end products (AGEs) are formed from amino acids and reducing sugars through nonenzymatic Maillard reaction. AGEs are known to induce oxidative stress, which may cause fibrosis or cancer. In this study, we investigated the protective effect of caffeic acid (CA) on AGE-mediated kidney epithelial to mesenchymal transition (EMT) in human HK-2 cells. Exposure to 100 µg/mL of AGEs by kidney epithelial cells raised the production of reactive oxygen species by 5.2-fold and decreased levels of glutathione. In addition, cardamonin, a ß-catenin inhibitor, was used to determine the signaling pathway for ß-catenin in which cardamonin inhibited the AGEs-induced translocation of ß-catenin into the nucleus, resulting in an inhibition of the EMT process. Similarly, our findings showed that, close to the control level, CA treatment decreased AGE-mediated oxidative stress, loss of E-cadherin expression, and overexpression of α-smooth muscle actin and fibronectin by inactivation of the ß-catenin pathway. Furthermore, AGE treatment enhanced the expression of collagen type I (1.99-fold) as well as the activity of metalloproteinases 2 (1.86-fold) and 9 (2.79-fold), but such increase was inhibited by the pretreatment of CA. In conclusion, this study determined the inhibitory effect of CA on AGE-induced ß-catenin signaling, which prevented the occurrence of EMT in kidney epithelial cells. This suggests that CA may be a potential target for AGE-induced renal fibrosis. PRACTICAL APPLICATION: Exposure of kidney epithelial cells to advanced glycation end products (AGEs) leads to a rise in reactive oxygen species and a decrease in glutathione, thereby increasing oxidative stress that may cause fibrosis. However, treatment of kidney cells with caffeic acid (CA) prior to their exposure to AGEs lowers oxidative stress and decreases fibrosis. This research reveals the beneficial influence of CA on renal fibrosis in laboratory-cultured kidney cells (in vitro), which makes CA a potential therapeutic target for AGE-induced fibrosis.


Asunto(s)
Antioxidantes/farmacología , Ácidos Cafeicos/farmacología , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Enfermedades Renales/inducido químicamente , Enfermedades Renales/prevención & control , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Fibrosis/inducido químicamente , Fibrosis/prevención & control , Productos Finales de Glicación Avanzada/efectos adversos , Humanos , Albúmina Sérica Bovina/farmacología
16.
Mol Biol Rep ; 48(1): 787-805, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33389535

RESUMEN

Advanced glycation end products (AGEs) are naturally occurring biomolecules formed by interaction of reducing sugars with biomolecules such as protein and lipids etc., Long term high blood sugar level and glycation accelerate the formation of AGEs. Unchecked continuous formation and accumulation of AGEs are potential risks for pathogenesis of various chronic diseases. Current mode of antidiabetic therapy is based on synthetic drugs that are often linked with severe adverse effects. Polyphenolic compounds derived from plants are supposed to inhibit glycation and formation of AGEs at multiple levels. Some polyphenolic compounds regulate the blood glucose metabolism by amplification of cell insulin resistance and activation of insulin like growth factor binding protein signaling pathway. Their antioxidant nature and metal chelating activity, ability to trap intermediate dicarbonyl compounds could be possible mechanisms against glycation and AGEs formation and hence, against AGEs induced health complications. Although, few species of polyphenolic compounds are being used in in vitro trials and their in vivo study is still in progress, increasing the area of research in this field may produce a fruitful approach in management of overall diabetic complications.


Asunto(s)
Antioxidantes/uso terapéutico , Diabetes Mellitus/tratamiento farmacológico , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Hipoglucemiantes/uso terapéutico , Obesidad/tratamiento farmacológico , Fitoquímicos/uso terapéutico , Polifenoles/uso terapéutico , Glucemia/metabolismo , Diabetes Mellitus/genética , Diabetes Mellitus/metabolismo , Diabetes Mellitus/patología , Regulación de la Expresión Génica , Productos Finales de Glicación Avanzada/genética , Productos Finales de Glicación Avanzada/metabolismo , Glicosilación , Humanos , Resistencia a la Insulina , Proteína 1 de Unión a Factor de Crecimiento Similar a la Insulina/genética , Proteína 1 de Unión a Factor de Crecimiento Similar a la Insulina/metabolismo , Obesidad/genética , Obesidad/metabolismo , Obesidad/patología , Transducción de Señal
17.
Eur J Pharmacol ; 894: 173874, 2021 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-33460615

RESUMEN

Hyperglycemic milieu in diabetes mellitus stimulates macrophages for exaggerated pro-inflammatory cytokine response, particularly IL-1ß, IL-6, and TNF-α. Although hyperglycemia causes macrophages to produce pro-inflammatory cytokines, AGEs (advanced glycation end products) active inflammation, produced as a result of chronic hyperglycemia, inducers cause polarization of macrophages into pro-inflammatory M1 phenotype. AGEs in diabetes accelerate atherosclerotic plaque initiation and progression via promoting macrophages polarization towards pro-inflammatory state. Gliclazide (Glz) is a well known antidiabetic drug with excellent safety profile. Its repurposing in the management of diabetes-associated late complications has tremendous merit. The present study demonstrated that Glz retards diabetic atherosclerotic progression, and cytokines storm in a concentration dependent manner over a concentration range of 1-100 µM than those of AGEs (200 µg/ml)-treated cells through a mechanism that alters macrophage M1 polarization state. Glz exerted these beneficial effects, independent of its antidiabetic effect. Glz pretreatment significantly (P < 0.05) inhibited the AGEs-induced pro-inflammatory mediators (NO•, reactive oxygen species, i-NOS), and production of pro-inflammatory cytokines, including IL-1ß, IL-6, and TNF-α. It also significantly (P < 0.05) promoted the production of anti-inflammatory cytokines (IL-10 and TGF-ß) in RAW 264.7 mouse macrophages. Glz pretreatment also effectively abated the AGEs-induced RAGE (~2-fold decrease), and CD86 surface marker expressions (P < 0.001 at 100 µM) on macrophages by inhibiting the NF-kß activation in a concentration dependent manner (1-100 µM) (P < 0.001). In conclusion, our data demonstrates that Glz alleviates the diabetic atherosclerosis progression by ameliorating the AGEs-mediated M1 pro-inflammatory phenotype via blocking AGE-RAGE/TLR4-reactive oxygen species -activated NF-kß nexus in macrophages.


Asunto(s)
Aterosclerosis/tratamiento farmacológico , Complicaciones de la Diabetes/tratamiento farmacológico , Gliclazida/farmacología , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Receptor para Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Animales , Antígenos de Superficie/efectos de los fármacos , Aterosclerosis/etiología , Supervivencia Celular/efectos de los fármacos , Citocinas/metabolismo , Diabetes Mellitus/metabolismo , Activación de Macrófagos/efectos de los fármacos , Macrófagos/efectos de los fármacos , Ratones , Subunidad p50 de NF-kappa B/antagonistas & inhibidores , Subunidad p50 de NF-kappa B/metabolismo , Óxido Nítrico Sintasa de Tipo II/efectos de los fármacos , Óxido Nítrico Sintasa de Tipo II/metabolismo , Células RAW 264.7 , Especies Reactivas de Oxígeno/antagonistas & inhibidores , Transducción de Señal/efectos de los fármacos , Receptor Toll-Like 4/antagonistas & inhibidores
18.
Molecules ; 26(1)2021 Jan 04.
Artículo en Inglés | MEDLINE | ID: mdl-33406776

RESUMEN

Muehlenbeckia volcanica (Benth.) Endl. (M. volcanica), native to South America, is a traditional Peruvian medicinal plant that has multi-therapeutic properties; however, no phytochemicals have been identified from it yet. In this study, a five-step polarity-stepwise elution counter-current chromatography (CCC) was developed using methanol/water (1:5, v/v) as the stationary phase and different ratios of n-hexane, ethyl acetate, and n-butanol as mobile phases to separate the compounds from the 70% methanol extract of M. volcanica, by which six compounds with a wide range of polarities were separated in a single run of CCC and were identified as gallic acid, protocatechuic acid, 4,4'-dihydroxy-3,3'-imino-di-benzoic acid, rutin, quercitrin, and quercetin. Then, two compounds from the fractions of stepwise elution CCC were separated using conventional high-speed CCC, pH-zone-refining CCC, and preparative high-performance liquid chromatography, and identified as shikimic acid and miquelianin. These compounds are reported from M. volcanica for the first time. Notably, except for shikimic acid, all other compounds showed anti-diabetic potentials via antioxidant, antiglycation, and aldose reductase inhibition. The results suggest that the polarity-stepwise elution CCC can be used to efficiently separate or fractionate compounds with a wide range of polarities from natural products. Moreover, M. volcanica and its bioactive compounds are potent anti-diabetic agents.


Asunto(s)
Aldehído Reductasa/antagonistas & inhibidores , Antioxidantes/farmacología , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Fitoquímicos/aislamiento & purificación , Fitoquímicos/farmacología , Extractos Vegetales/farmacología , Polygonaceae/química , Cromatografía Líquida de Alta Presión , Distribución en Contracorriente
19.
J Ethnopharmacol ; 271: 113865, 2021 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-33485975

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Flavonoids interact with multiple targets in Central Nervous System resulting in a broad neuroprotection mediated by complementary processes and synergic interactions. Therefore, flavonoid-based therapies may input positive outcomes in the prevention and early management of neurodegenerative diseases. In Brazilian folk medicine Trichilia catigua is used for its neuroactive properties, such as neurostimulant, antioxidant and anti-neuroinflammatory, while Turnera diffusa is traditionally used as a tonic in neurasthenia. Both species are known to be rich in flavonoids. AIM OF THE STUDY: To study aqueous extracts of T. catigua and T. diffusa in terms of their antioxidant and antiglycation effects, inhibition of tyrosinase activity, and interaction with enzymes and pathways engaged in neuroinflammation. Moreover, whenever possible, to establish a relationship between the studied activities and the traditional usage of the species. MATERIALS AND METHODS: The phenolic profiles of the aqueous extracts were validated by HPLC-DAD. The effect of the extracts over mushroom tyrosinase and 5-lipoxygenase activities, as well as their capacity to impair bovine serum albumin glycation, were assessed by in vitro assays. The anti-neuroinflammatory potential of the same extracts was evaluated by their capacity to mitigate the pro-inflammatory stimulus induced in BV-2 microglia cells by interferon-gamma. RESULTS: T. catigua extract, a rich mixture of phenolic acids, catechins and flavonolignans, excels by its ability to decrease lipid peroxidation (EC50 = 227.18 ±â€¯9.04 µg/mL), and to work as anti-glycation agent, and inhibitor of both tyrosinase and 5-lipoxigenase (IC50 = 358.84 ±â€¯19.05 and 56.25 ±â€¯14.53 µg/mL, respectively). However, only T. diffusa extract, mainly composed by luteolin derivatives, is able to lower NO production by BV-2 microglia cells stimulated with interferon-gamma, despite its lower activities in the other assays. CONCLUSIONS: Overall, this work highlights the value of medicinal plant extracts as sources of bioactive flavonoid-rich extracts with neuroactive effects. Furthermore, these results support their application as alternative strategies to develop functional foods and therapeutics to fight chronic neurodegenerative disorders.


Asunto(s)
Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Meliaceae/química , Monofenol Monooxigenasa/antagonistas & inhibidores , Fármacos Neuroprotectores/farmacología , Extractos Vegetales/farmacología , Turnera/química , Animales , Antioxidantes/farmacología , Brasil , Línea Celular , Supervivencia Celular/efectos de los fármacos , Productos Finales de Glicación Avanzada/efectos de los fármacos , Inflamación/metabolismo , Peroxidación de Lípido/efectos de los fármacos , Inhibidores de la Lipooxigenasa/farmacología , Medicina Tradicional , Ratones , Microglía/efectos de los fármacos , Óxido Nítrico/metabolismo
20.
Sci Rep ; 11(1): 1895, 2021 01 21.
Artículo en Inglés | MEDLINE | ID: mdl-33479339

RESUMEN

Formation of advanced glycation end products (AGEs), which are associated with diabetes mellitus, contributes to prominent features of osteoarthritis, i.e., inflammation-mediated destruction of articular cartilage. Among the phytochemicals which play a role in anti-inflammatory effects, anthocyanins have also been demonstrated to have anti-diabetic properties. Purple corn is a source of three major anthocyanins: cyanidin-3-O-glucoside, pelargonidin-3-O-glucoside and peonidin-3-O-glucoside. Purple corn anthocyanins have been demonstrated to be involved in the reduction of diabetes-associated inflammation, suggesting that they may have a beneficial effect on diabetes-mediated inflammation of cartilage. This investigation of the chondroprotective effects of purple corn extract on cartilage degradation found a reduction in glycosaminoglycans released from AGEs induced cartilage explants, corresponding with diminishing of uronic acid loss of the cartilage matrix. Investigation of the molecular mechanisms in human articular chondrocytes showed the anti-inflammatory effect of purple corn anthocyanins and the metabolite, protocatechuic acid (PCA) on AGEs induced human articular chondrocytes via inactivation of the NFκb and MAPK signaling pathways. This finding suggests that purple corn anthocyanins and PCA may help ameliorate AGEs mediated inflammation and diabetes-mediated cartilage degradation.


Asunto(s)
Antocianinas/farmacología , Complicaciones de la Diabetes/tratamiento farmacológico , Productos Finales de Glicación Avanzada/genética , Inflamación/tratamiento farmacológico , Antocianinas/química , Cartílago/efectos de los fármacos , Cartílago/patología , Línea Celular , Condrocitos/efectos de los fármacos , Condrocitos/patología , Complicaciones de la Diabetes/genética , Complicaciones de la Diabetes/patología , Diabetes Mellitus/tratamiento farmacológico , Diabetes Mellitus/metabolismo , Diabetes Mellitus/patología , Glucósidos/química , Glucósidos/farmacología , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Glicosaminoglicanos/genética , Humanos , Hidroxibenzoatos/toxicidad , Inflamación/complicaciones , Inflamación/genética , Inflamación/patología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , FN-kappa B/genética , Osteoartritis/inducido químicamente , Osteoartritis/tratamiento farmacológico , Osteoartritis/genética , Osteoartritis/patología , Zea mays/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...